|
DE2611690A1
(de)
*
|
1976-03-19 |
1977-09-22 |
Goedecke Ag |
Cyclische sulfonyloxyimide
|
|
JPS5776189U
(enExample)
*
|
1980-10-28 |
1982-05-11 |
|
|
|
JPS6152583U
(enExample)
*
|
1984-09-11 |
1986-04-09 |
|
|
|
JPS61139881U
(enExample)
*
|
1985-02-21 |
1986-08-29 |
|
|
|
US4876279A
(en)
*
|
1986-05-05 |
1989-10-24 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
|
US4894476A
(en)
*
|
1988-05-02 |
1990-01-16 |
Warner-Lambert Company |
Gabapentin monohydrate and a process for producing the same
|
|
US4960931A
(en)
*
|
1988-05-02 |
1990-10-02 |
Warner-Lambert Company |
Gabapentin mohohydrate and a process for producing the same
|
|
YU162789A
(en)
*
|
1988-09-01 |
1990-12-31 |
Lonza Ag |
2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones
|
|
DE3928183A1
(de)
*
|
1989-08-25 |
1991-02-28 |
Goedecke Ag |
Lactamfreie cyclische aminosaeuren
|
|
US5132451A
(en)
*
|
1989-08-25 |
1992-07-21 |
Warner-Lambert Company |
Process for cyclic amino acid anticonvulsant compounds
|
|
PH27359A
(en)
*
|
1989-08-25 |
1993-06-21 |
Warner Lambert Co |
Process for cyclic amino acid anticonvulsant compounds
|
|
DE3928182A1
(de)
|
1989-08-25 |
1991-02-28 |
Goedecke Ag |
Verfahren zur herstellung von gabapentin
|
|
DE3928184A1
(de)
*
|
1989-08-25 |
1991-02-28 |
Goedecke Ag |
Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
|
|
US5319135A
(en)
*
|
1989-08-25 |
1994-06-07 |
Warner-Lambert Company |
Process for cyclic amino acid anticonvulsant compounds
|
|
US5149870A
(en)
*
|
1989-11-16 |
1992-09-22 |
Lonza Ltd. |
Process for the production of 1-(aminomethyl)cyclohexane acetic acid
|
|
US5260467A
(en)
*
|
1989-11-16 |
1993-11-09 |
Pfizer Inc. |
Glutaric acid derivatives and preparation thereof
|
|
US5136091A
(en)
*
|
1989-11-16 |
1992-08-04 |
Lonza Ltd. |
Process for the production of 1-(aminomethyl) cyclohexane acetic acid
|
|
FI905584L
(fi)
*
|
1989-11-16 |
1991-05-17 |
Lonza Ag |
Foerfarande foer framstaellning av 1-(aminometyl)cyklohexanaettikssyra.
|
|
GB8925933D0
(en)
*
|
1989-11-16 |
1990-01-04 |
Pfizer Ltd |
Glutaric acid derivatives and preparation thereof
|
|
US5157138A
(en)
*
|
1989-11-16 |
1992-10-20 |
Pfizer, Inc. |
Glutaric acid derivatives and preparation thereof
|
|
US5084479A
(en)
*
|
1990-01-02 |
1992-01-28 |
Warner-Lambert Company |
Novel methods for treating neurodegenerative diseases
|
|
US5025035A
(en)
*
|
1990-10-12 |
1991-06-18 |
Warner-Lambert Company |
Method of treating depression
|
|
US5792796A
(en)
*
|
1994-07-27 |
1998-08-11 |
Warner-Lambert Company |
Methods for treating anxiety and panic
|
|
US5510381A
(en)
*
|
1995-05-15 |
1996-04-23 |
Warner-Lambert Company |
Method of treatment of mania and bipolar disorder
|
|
DE69712877T2
(de)
*
|
1996-02-07 |
2002-11-14 |
Warner-Lambert Co., Morris Plains |
Zyklischaminosäure als pharmazeutische mittel
|
|
EA001214B1
(ru)
*
|
1996-03-14 |
2000-12-25 |
Варнер-Ламберт Компани |
Новые мостиковые циклические аминокислоты как фармацевтически применимые вещества
|
|
DK0888286T3
(da)
*
|
1996-03-14 |
2002-02-18 |
Warner Lambert Co |
Nye substituerede cykliske aminosyrer som farmaceutiske midler
|
|
EP0934061B3
(en)
|
1996-07-24 |
2015-01-21 |
Warner-Lambert Company LLC |
Isobutylgaba and its derivatives for the treatment of pain
|
|
NZ334898A
(en)
*
|
1996-10-23 |
2000-09-29 |
Warner Lambert Co |
Substituted gamma aminobutyric acids as pharamceutical agents
|
|
IL119890A
(en)
*
|
1996-12-24 |
2002-03-10 |
Teva Pharma |
Gabapentin form iii and preparation of gabapentin form ii
|
|
US6255526B1
(en)
|
1996-12-24 |
2001-07-03 |
Teva Pharmaceutical Industries Ltd. |
Preparation of gabapentin
|
|
HRP980342A2
(en)
*
|
1997-06-25 |
1999-02-28 |
Warner Lambert Co |
Anti-inflammatory method
|
|
US6329429B1
(en)
|
1997-06-25 |
2001-12-11 |
Warner-Lambert Company |
Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
|
|
US6194459B1
(en)
|
1997-08-19 |
2001-02-27 |
Warner-Lambert Company |
Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants
|
|
WO1999012537A1
(en)
*
|
1997-09-08 |
1999-03-18 |
Warner-Lambert Company |
Analgesic compositions comprising anti-epileptic compounds and methods of using same
|
|
US6294690B1
(en)
|
1997-10-07 |
2001-09-25 |
Warner-Lambert Company |
Process for preparing a cyclic amino acid anticonvulsant compound
|
|
ATE323067T1
(de)
|
1997-10-27 |
2006-04-15 |
Warner Lambert Co |
Zyklische aminosäuren und deren derivate als arzneimittel
|
|
US6984659B2
(en)
*
|
1997-11-18 |
2006-01-10 |
Klinikum Der Albert-Ludwigs Universitaet |
2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
|
|
CN1279667A
(zh)
|
1997-12-16 |
2001-01-10 |
沃尼尔·朗伯公司 |
4(3)取代-4(3)-氨基甲基-(硫代)吡喃(噻喃)或-哌啶衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
|
|
WO1999031074A2
(en)
|
1997-12-16 |
1999-06-24 |
Warner-Lambert Company |
((cyclo)alkyl substituted)-.gamma.-aminobutyric acid derivatives (=gaba analogues), their preparation and their use in the treatment of neurological disorders
|
|
NZ503963A
(en)
*
|
1997-12-16 |
2002-09-27 |
Warner Lambert Co |
1-substituted-1-aminomethyl-cycloalkane derivatives, or gabapentin analogues, preparation and use in the treatment of neurological disorders
|
|
CA2309354A1
(en)
*
|
1998-01-23 |
1999-07-29 |
Leslie Magnus-Miller |
Gabapentin and its derivatives for the treatment of muscular and skeletal pain
|
|
EP0974351A3
(en)
*
|
1998-04-24 |
2000-12-13 |
Jouveinal |
Medicament for preventing and treating gastrointestinal damage
|
|
CA2327285C
(en)
|
1998-05-15 |
2005-06-14 |
Warner-Lambert Company |
Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
|
|
WO1999059572A1
(en)
*
|
1998-05-15 |
1999-11-25 |
Warner-Lambert Company |
Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
|
|
ES2137137B1
(es)
*
|
1998-05-25 |
2000-08-16 |
Medichem Sa |
Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
|
|
JP2002516312A
(ja)
|
1998-05-26 |
2002-06-04 |
ワーナー−ランバート・カンパニー |
カルシウムチャンネルのα2δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物
|
|
ITMI981535A1
(it)
*
|
1998-07-03 |
2000-01-03 |
Zambon Spa |
Processo per la preparazione di gabapentina
|
|
US20030045500A1
(en)
*
|
1998-07-09 |
2003-03-06 |
Leslie Magnus |
Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
|
|
FR2781793B1
(fr)
|
1998-08-03 |
2001-07-20 |
Prographarm Lab |
Procede de fabrication de granules de gabapentine enrobes
|
|
HU225502B1
(en)
*
|
1998-12-29 |
2007-01-29 |
Richter Gedeon Vegyeszet |
Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates
|
|
IT1311984B1
(it)
|
1999-03-26 |
2002-03-22 |
Bioindustria Lab Italiano Medi |
Procedimento per la preparzione di gabapentin.
|
|
AU4334900A
(en)
*
|
1999-04-09 |
2000-11-14 |
Euro-Celtique S.A. |
Sodium channel blocker compositions and the use thereof
|
|
US6710190B1
(en)
*
|
1999-05-28 |
2004-03-23 |
Warner-Lambert Company |
3-heteroarylalkyl substituted gaba analogs
|
|
PT1185524E
(pt)
*
|
1999-05-28 |
2005-04-29 |
Warner Lambert Co |
Analogos de gaba substituidos por 3-heteroarilalquilo
|
|
CZ300834B6
(cs)
*
|
1999-06-10 |
2009-08-19 |
Warner-Lambert Company Llc |
Mono- a disubstituované kyseliny 3-propyl-gamma-aminomáselné
|
|
US7164034B2
(en)
*
|
1999-06-10 |
2007-01-16 |
Pfizer Inc. |
Alpha2delta ligands for fibromyalgia and other disorders
|
|
US20080207755A1
(en)
*
|
2000-05-31 |
2008-08-28 |
Pfizer Inc |
Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
|
|
US6294198B1
(en)
|
1999-08-24 |
2001-09-25 |
Purepac Pharmaceutical Co. |
Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
|
|
HN2000000224A
(es)
*
|
1999-10-20 |
2001-04-11 |
Warner Lambert Co |
Aminoacidos biciclicos como agentes farmaceuticos
|
|
GB2362646A
(en)
*
|
2000-05-26 |
2001-11-28 |
Warner Lambert Co |
Cyclic amino acid derivatives useful as pharmaceutical agents
|
|
EP1384473A1
(en)
*
|
2000-06-16 |
2004-01-28 |
Teva Pharmaceutical Industries Ltd. |
Stable gabapentin containing more than 20 ppm of chlorine ion
|
|
CA2411787C
(en)
*
|
2000-06-16 |
2007-03-20 |
Teva Pharmaceuticals Industries Ltd. |
Stable gabapentin having ph within a controlled range
|
|
CA2410867C
(en)
|
2000-06-16 |
2003-12-09 |
Claude Singer |
Stable gabapentin containing more than 2o ppm of chlorine ion
|
|
NZ522480A
(en)
*
|
2000-06-26 |
2005-06-24 |
Warner Lambert Co |
Gabapentin analogues for sleep disorders
|
|
GB2364049A
(en)
*
|
2000-06-28 |
2002-01-16 |
Warner Lambert Co |
Cyclic ketones and their use in the synthesis of amino acids
|
|
NZ525143A
(en)
*
|
2000-09-14 |
2005-12-23 |
Gruenenthal Chemie |
Beta-thio-amino acids
|
|
AU2002230398A1
(en)
*
|
2000-10-06 |
2002-04-29 |
Xenoport, Inc. |
Bile-acid conjugates for providing sustained systemic concentrations of drugs
|
|
WO2002028881A1
(en)
*
|
2000-10-06 |
2002-04-11 |
Xenoport, Inc. |
Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
|
|
US6620829B2
(en)
*
|
2000-10-17 |
2003-09-16 |
Warner-Lambert Company |
Method of treating noninflammatory cartilage damage
|
|
IT1319234B1
(it)
*
|
2000-10-23 |
2003-09-26 |
Zambon Spa |
Processo di preparazione di gabapentina.
|
|
GB2368579A
(en)
*
|
2000-10-31 |
2002-05-08 |
Parke Davis & Co Ltd |
Azole pharmaceutical agents
|
|
JP2004530637A
(ja)
*
|
2000-11-02 |
2004-10-07 |
テバ ファーマシューティカル インダストリーズ リミティド |
ガバペンチン中間体の製造のための改善方法
|
|
KR20030059290A
(ko)
*
|
2000-11-30 |
2003-07-07 |
화이자 프로덕츠 인코포레이티드 |
Gaba 작용제 및 소르비톨 데하이드로게나제 억제제의혼합물
|
|
AP2001002359A0
(en)
*
|
2000-11-30 |
2001-12-31 |
Pfizer Prod Inc |
Combination of gaba agonists and aldose reductase inhibitors.
|
|
IT1319674B1
(it)
*
|
2000-12-01 |
2003-10-23 |
Erregierre Spa |
Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
|
|
US20040063994A1
(en)
*
|
2001-03-16 |
2004-04-01 |
Paolo Rossi |
Process for the preparation of cyclic amino acids
|
|
ITMI20011132A1
(it)
|
2001-05-29 |
2002-11-29 |
Procos Spa |
Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico
|
|
EP1412324A4
(en)
*
|
2001-06-11 |
2004-09-29 |
Xenoport Inc |
AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
|
|
US6818787B2
(en)
*
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
|
US7186855B2
(en)
|
2001-06-11 |
2007-03-06 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
|
AU2002310409C1
(en)
*
|
2001-06-11 |
2008-04-17 |
Xenoport, Inc. |
Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
|
|
US8048917B2
(en)
*
|
2005-04-06 |
2011-11-01 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
|
US7232924B2
(en)
*
|
2001-06-11 |
2007-06-19 |
Xenoport, Inc. |
Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
|
|
IL144066A0
(en)
*
|
2001-06-28 |
2002-04-21 |
Bromine Compounds Ltd |
Process for the preparation of 1,1-cyclohexane diacetic monoamide
|
|
ITMI20011772A1
(it)
|
2001-08-10 |
2003-02-10 |
A M S A Anonima Materie Sint E |
Processo per la preparazione della 2,5-bis-(2,2,2-trifluoroetossi)-n-(2-piperidilmetil)-benzamide(flecainide)
|
|
CN1274306C
(zh)
|
2001-09-03 |
2006-09-13 |
纽朗制药有限公司 |
包含加巴喷丁或其类似物和α-氨基酰胺的药物组合物及其止痛应用
|
|
US6800782B2
(en)
*
|
2001-10-09 |
2004-10-05 |
Warner-Lambert Co. |
Anhydrous crystalline forms of gabapentin
|
|
TWI312285B
(en)
*
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
|
US7612112B2
(en)
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
|
US20070184104A1
(en)
*
|
2001-10-25 |
2007-08-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
|
US20060159743A1
(en)
*
|
2001-10-25 |
2006-07-20 |
Depomed, Inc. |
Methods of treating non-nociceptive pain states with gastric retentive gabapentin
|
|
US20030119908A1
(en)
*
|
2001-12-21 |
2003-06-26 |
Zambon Group S.P.A. |
Stable gabapentin compositions
|
|
ITMI20012750A1
(it)
|
2001-12-21 |
2003-06-21 |
Procos Spa |
Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
|
|
PL371944A1
(en)
*
|
2002-01-31 |
2005-07-11 |
Warner-Lambert Company Llc |
Alpha 2 delta ligands to treat tinnitus
|
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
|
US6927036B2
(en)
*
|
2002-02-19 |
2005-08-09 |
Xero Port, Inc. |
Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
|
|
WO2003080588A1
(en)
*
|
2002-03-20 |
2003-10-02 |
Xenoport |
Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
|
|
CA2478471A1
(en)
*
|
2002-04-16 |
2003-10-30 |
Taro Pharmaceutical Industries Ltd. |
Process for preparing gabapentin
|
|
WO2003094842A2
(en)
*
|
2002-05-07 |
2003-11-20 |
A & D Bioscience, Inc. |
Conjugates comprising central nervous system active drug
|
|
WO2003099338A2
(en)
*
|
2002-05-17 |
2003-12-04 |
Xenoport, Inc. |
Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
|
|
JP2005534678A
(ja)
*
|
2002-06-27 |
2005-11-17 |
ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー |
注意欠陥多動性障害の治療方法
|
|
CA2395931A1
(en)
*
|
2002-08-07 |
2004-02-07 |
Bernard Charles Sherman |
Solid compositions comprising gabapentin having improved stability
|
|
US7053122B2
(en)
*
|
2002-08-09 |
2006-05-30 |
Pfizer Inc |
Therapeutic use of aryl amino acid derivatives
|
|
US7419981B2
(en)
*
|
2002-08-15 |
2008-09-02 |
Pfizer Inc. |
Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
|
|
US20040092522A1
(en)
*
|
2002-08-15 |
2004-05-13 |
Field Mark John |
Synergistic combinations
|
|
US20040092591A1
(en)
*
|
2002-08-15 |
2004-05-13 |
Blakemore David Clive |
Therapeutic use of fused bicyclic or tricyclic amino acids
|
|
US20040092498A1
(en)
*
|
2002-08-16 |
2004-05-13 |
David Blakemore |
Substituted glycine derivatives for use as medicaments
|
|
ITMI20022071A1
(it)
*
|
2002-10-01 |
2004-04-02 |
Erregierre Spa |
Processo di sintesi dell'acido 1-(aminometil)cicloesanacetico cloridato.
|
|
US7659305B2
(en)
*
|
2002-10-31 |
2010-02-09 |
Pfizer Inc. |
Therapeutic proline derivatives
|
|
US7196216B2
(en)
*
|
2002-11-18 |
2007-03-27 |
Nicholas Piramal India Limited |
Process for preparation of Gabapentin
|
|
EP1599446B1
(en)
*
|
2002-11-20 |
2009-08-12 |
Hikal Ltd. |
An improved process for the preparation of gabalactam
|
|
AU2003297909A1
(en)
*
|
2002-12-11 |
2004-06-30 |
Xenoport, Inc. |
Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
|
|
AU2003297927A1
(en)
*
|
2002-12-11 |
2004-06-30 |
Xenoport, Inc. |
Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
|
|
CA2451267A1
(en)
*
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
|
EP2172197A1
(en)
*
|
2002-12-13 |
2010-04-07 |
Warner-Lambert Company LLC |
Octanoic acid derivative to treat fibromyalgia and other pains
|
|
AU2003286300A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Warner-Lambert Company Llc |
Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders
|
|
US20040180958A1
(en)
*
|
2002-12-13 |
2004-09-16 |
Taylor Charles Price |
Method of treatment
|
|
AU2003283718A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Warner-Lambert Company Llc |
Gabapentin analogues for fibromyalgia and other related disorders
|
|
PT1572173E
(pt)
|
2002-12-13 |
2010-05-10 |
Warner Lambert Co |
Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
|
|
GB0301143D0
(en)
*
|
2003-01-17 |
2003-02-19 |
Amedis Pharm Ltd |
Compounds and their use
|
|
PL377937A1
(pl)
*
|
2003-01-22 |
2006-02-20 |
Warner-Lambert Company Llc |
Pochodne cyklopropylo-beta-aminokwasu
|
|
WO2004078734A1
(en)
*
|
2003-03-07 |
2004-09-16 |
Warner-Lambert Company Llc |
TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES
|
|
WO2004093866A1
(en)
*
|
2003-03-25 |
2004-11-04 |
Kiel Laboratories, Inc. |
Process for preparing phenolic acid salts of gabapentin
|
|
EP1622603A4
(en)
*
|
2003-03-25 |
2010-03-24 |
Kiel Lab Inc |
GABAPENTINIC PHENOLIC ACID SALTS IN SOLID DOSAGE FORMS AND METHODS OF USE
|
|
WO2004093867A2
(en)
*
|
2003-03-25 |
2004-11-04 |
Kiel Laboratories, Inc. |
Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use
|
|
MXPA05010515A
(es)
*
|
2003-03-31 |
2006-03-10 |
Xenoport Inc |
Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
|
|
US20040214893A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Matthew Peterson |
Gabapentin compositions
|
|
ITMI20030825A1
(it)
*
|
2003-04-18 |
2004-10-19 |
Farchemia Srl |
Procedimento per la preparazione di gabapentin esente da
|
|
US7439387B2
(en)
*
|
2003-04-21 |
2008-10-21 |
Matrix Laboratories Ltd. |
Process for the preparation of Gabapentin form-II
|
|
CA2525366A1
(en)
*
|
2003-05-16 |
2004-11-25 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
|
|
CA2528388A1
(en)
*
|
2003-06-19 |
2004-12-23 |
Pfizer Products Inc. |
Biocatalytic preparation of 1-cyanocyclohexaneacetic acid
|
|
US7169812B2
(en)
*
|
2003-07-01 |
2007-01-30 |
Medtronic, Inc. |
Process for producing injectable gabapentin compositions
|
|
WO2005002585A1
(en)
*
|
2003-07-02 |
2005-01-13 |
Warner-Lambert Company Llc |
Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
|
|
US20050013863A1
(en)
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
|
WO2005046566A2
(en)
*
|
2003-08-04 |
2005-05-26 |
Sun Pharmaceutical Industries Limited |
Stable gabapentin containing composition
|
|
US20050043407A1
(en)
*
|
2003-08-22 |
2005-02-24 |
Pfizer Inc |
Pharmaceutical composition for the prevention and treatment of addiction in a mammal
|
|
CA2537837A1
(en)
*
|
2003-09-11 |
2005-03-24 |
Xenoport, Inc. |
Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
|
|
WO2005025563A1
(en)
*
|
2003-09-12 |
2005-03-24 |
Warner-Lambert Company Llc |
Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
|
|
ATE449633T1
(de)
*
|
2003-09-12 |
2009-12-15 |
Pfizer |
Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
|
|
CA2538802C
(en)
*
|
2003-09-17 |
2015-01-27 |
Xenoport, Inc. |
Treating or preventing restless legs syndrome using prodrugs of gaba analogs
|
|
CA2541752C
(en)
|
2003-10-14 |
2012-01-03 |
Xenoport, Inc. |
Crystalline form of gamma-aminobutyric acid analog
|
|
ITMI20032165A1
(it)
*
|
2003-11-11 |
2005-05-12 |
Zambon Spa |
Processo di preparazione di gabapentina
|
|
PT1691811E
(pt)
|
2003-12-11 |
2014-10-30 |
Sunovion Pharmaceuticals Inc |
Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
|
|
BRPI0507190A
(pt)
*
|
2004-01-29 |
2007-06-26 |
Pfizer Prod Inc |
combinação de moduladores do ácido gama-aminobutìrico e antagonistas de 5-ht1b receptores
|
|
US20050187295A1
(en)
*
|
2004-02-19 |
2005-08-25 |
Surendra Kalyan |
Processes for the preparation of gabapentin
|
|
WO2005087709A1
(en)
*
|
2004-03-17 |
2005-09-22 |
Hikal Limited |
4-t-butylgabapentin and its synthesis
|
|
ITMI20040579A1
(it)
*
|
2004-03-25 |
2004-06-25 |
Zambon Spa |
Processo di preparazione di gabapentina
|
|
EP1737473A4
(en)
*
|
2004-04-19 |
2009-08-26 |
Noven Therapeutics Llc |
COMBINATIONS OF LITHIUM AND USES THEREOF
|
|
BRPI0511941A
(pt)
*
|
2004-06-09 |
2008-01-22 |
Pfizer |
uso de (s, s)-reboxetina ou reboxetina racêmica
|
|
GB0416228D0
(en)
*
|
2004-07-20 |
2004-08-25 |
Sandoz Ind Products S A |
Process for the preparation of gabapentin
|
|
GB0419849D0
(en)
*
|
2004-09-07 |
2004-10-13 |
Pfizer Ltd |
Pharmaceutical combination
|
|
RS51411B
(sr)
*
|
2004-09-10 |
2011-02-28 |
Newron Pharmaceuticals S.P.A. |
Upotreba (r)-(halobenziloksi) benzilamino-propanamida kao selektivnih modulatora natrijumovih i/ili kalcijumovih kanala
|
|
EP1811986B1
(en)
*
|
2004-11-04 |
2014-03-26 |
XenoPort, Inc. |
Gabapentin prodrug sustained release oral dosage forms
|
|
EP2275096A3
(en)
|
2005-08-26 |
2011-07-13 |
Braincells, Inc. |
Neurogenesis via modulation of the muscarinic receptors
|
|
EP2258357A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
US8378096B2
(en)
*
|
2005-09-23 |
2013-02-19 |
Janssen Pharmaceutica N.V. |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
|
BRPI0616263A2
(pt)
|
2005-09-23 |
2011-06-14 |
Janssen Pharmaceutica Nv |
moduladores canabinàides do tipo tetrahidro-ciclopentil pirazol
|
|
ES2375213T3
(es)
*
|
2005-09-23 |
2012-02-27 |
Janssen Pharmaceutica Nv |
Moduladores de cannabinoides de hexadhidro-cicloheptapirazol.
|
|
UA93389C2
(en)
*
|
2005-09-23 |
2011-02-10 |
Янссен Фармацевтика H.B. |
Hexahydro cyclooctyl pyrazole cannabinoid modulators
|
|
US7825151B2
(en)
*
|
2005-09-23 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Hexahydro-cyclooctyl pyrazole cannabinoid modulators
|
|
US8378117B2
(en)
*
|
2005-09-23 |
2013-02-19 |
Janssen Pharmaceutica N.V. |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
|
WO2007047978A2
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
EP2314289A1
(en)
|
2005-10-31 |
2011-04-27 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
US20070117858A1
(en)
*
|
2005-11-23 |
2007-05-24 |
Mingde Xia |
Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
|
|
US20090176882A1
(en)
*
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
|
EP1979593B1
(en)
*
|
2006-02-03 |
2017-12-06 |
Rolls-Royce Corporation |
Gas turbine engine fuel system with fuel metering valve
|
|
EP1820502A1
(en)
|
2006-02-10 |
2007-08-22 |
Laboratorios Del Dr. Esteve, S.A. |
Active substance combination comprising azolylcarbinol compounds
|
|
WO2007095513A1
(en)
*
|
2006-02-14 |
2007-08-23 |
Janssen Pharmaceutica, Nv |
Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators
|
|
CA2640402C
(en)
*
|
2006-03-06 |
2012-01-03 |
Pfizer Products Inc. |
Alpha-2-delta ligands for non-restorative sleep
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US20070254911A1
(en)
*
|
2006-03-27 |
2007-11-01 |
Mingde Xia |
Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
|
|
WO2007112402A1
(en)
*
|
2006-03-27 |
2007-10-04 |
Janssen Pharmaceutica N.V. |
Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
|
|
EP2021000A2
(en)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
US7678808B2
(en)
|
2006-05-09 |
2010-03-16 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
|
US7442834B2
(en)
*
|
2006-06-12 |
2008-10-28 |
Zhejiang Chiral Medicine Chemicals Co., Ltd. |
Process suitable for industrial scale production of gabapentin
|
|
CN101484413B
(zh)
*
|
2006-06-30 |
2014-05-14 |
Zach系统股份公司 |
制备加巴喷丁的方法
|
|
WO2008030651A1
(en)
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
CA2672044A1
(en)
*
|
2006-12-08 |
2008-06-19 |
Xenoport, Inc. |
Use of prodrugs of gaba analogs for treating diseases
|
|
CN102058885B
(zh)
|
2006-12-22 |
2013-04-10 |
瑞蔻达蒂爱尔兰有限公司 |
采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
|
|
EP2118052A4
(en)
*
|
2007-03-15 |
2010-04-14 |
Sun Pharma Advanced Res Co Ltd |
NEW PRODRUGS
|
|
WO2008157408A2
(en)
*
|
2007-06-15 |
2008-12-24 |
Xenoport, Inc. |
Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
|
|
US7943653B2
(en)
*
|
2007-08-13 |
2011-05-17 |
Janssen Pharmaceutica N.V. |
Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
|
|
US20090062392A1
(en)
*
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched gabapentin
|
|
US20090118365A1
(en)
*
|
2007-11-06 |
2009-05-07 |
Xenoport, Inc |
Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
|
|
CA2710538A1
(en)
*
|
2008-01-25 |
2009-07-30 |
Xenoport, Inc. |
Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
|
|
WO2009094577A2
(en)
|
2008-01-25 |
2009-07-30 |
Xenoport, Inc. |
Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
|
|
WO2009094563A2
(en)
|
2008-01-25 |
2009-07-30 |
Xenoport, Inc. |
Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
|
|
EP2116539A1
(en)
|
2008-04-25 |
2009-11-11 |
Laboratorios Del. Dr. Esteve, S.A. |
1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
|
|
US20100190752A1
(en)
*
|
2008-09-05 |
2010-07-29 |
Gruenenthal Gmbh |
Pharmaceutical Combination
|
|
ES2589915T3
(es)
|
2008-10-08 |
2016-11-17 |
Xgene Pharmaceutical Inc |
Conjugados de GABA y métodos de utilización de los mismos
|
|
US9192681B2
(en)
|
2009-02-24 |
2015-11-24 |
Nektar Therapeutics |
Oligomer-amino acid conjugates
|
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
US20110130454A1
(en)
*
|
2009-11-24 |
2011-06-02 |
Xenoport, Inc. |
Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
|
|
US20110124705A1
(en)
*
|
2009-11-24 |
2011-05-26 |
Xenoport, Inc. |
Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
|
|
WO2011071995A2
(en)
|
2009-12-08 |
2011-06-16 |
Case Western Reserve University |
Compounds and methods of treating ocular disorders
|
|
EP2353591A1
(en)
|
2010-02-04 |
2011-08-10 |
Laboratorios Del. Dr. Esteve, S.A. |
Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
|
|
EP2368872A1
(en)
|
2010-03-25 |
2011-09-28 |
Serichim S.r.l. |
Process for the preparation of Gabapentin
|
|
EP2388005A1
(en)
|
2010-05-21 |
2011-11-23 |
Laboratorios Del. Dr. Esteve, S.A. |
Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
|
|
EP2575798B1
(en)
|
2010-06-01 |
2017-08-09 |
Rubicon Research Private Limited |
Gastroretentive dosage forms of gaba analogs
|
|
US8431739B2
(en)
|
2010-06-14 |
2013-04-30 |
Divi's Laboratories, Ltd. |
Process for the preparation of gabapentin
|
|
KR101786818B1
(ko)
|
2010-07-30 |
2017-10-18 |
도레이 카부시키가이샤 |
신경장애성 동통의 치료제 또는 예방제
|
|
EP2415471A1
(en)
|
2010-08-03 |
2012-02-08 |
Laboratorios Del. Dr. Esteve, S.A. |
Use of sigma ligands in opioid-induced hyperalgesia
|
|
JP2013216580A
(ja)
*
|
2010-08-06 |
2013-10-24 |
Kyorin Pharmaceutical Co Ltd |
ビシクロ[2.2.2]オクチルアミン誘導体の製造方法
|
|
EP2524694A1
(en)
|
2011-05-19 |
2012-11-21 |
Laboratorios Del. Dr. Esteve, S.A. |
Use of sigma ligands in diabetes type-2 associated pain
|
|
EP2530072A1
(en)
|
2011-06-03 |
2012-12-05 |
Lacer, S.A. |
New compounds, synthesis and use thereof in the treatment of pain
|
|
US9066853B2
(en)
|
2013-01-15 |
2015-06-30 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable fiber
|
|
ITMI20131757A1
(it)
|
2013-10-22 |
2015-04-23 |
Zach System Spa |
Processo di preparazione di gabapentina
|
|
WO2015064453A1
(ja)
|
2013-11-01 |
2015-05-07 |
株式会社糖鎖工学研究所 |
チオール基を有するd-体またはl-体アミノ酸誘導体の製造方法
|
|
SG11201604480PA
(en)
|
2013-12-17 |
2016-07-28 |
Esteve Labor Dr |
SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
|
|
MX2016007286A
(es)
|
2013-12-17 |
2016-08-04 |
Esteve Labor Dr |
Combinaciones de gabapentinoides y ligandos de receptores sigma.
|
|
WO2015144825A1
(en)
|
2014-03-27 |
2015-10-01 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Oral liquid pharmaceutical solution of gabapentin
|
|
HRP20220463T1
(hr)
|
2016-12-16 |
2022-05-27 |
Idorsia Pharmaceuticals Ltd |
Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa
|
|
MX384760B
(es)
|
2018-07-04 |
2025-03-14 |
Federico Amezcua Amezcua |
Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
|
|
US10399926B1
(en)
|
2018-08-01 |
2019-09-03 |
Divi's Laboratories Ltd. |
Process for the preparation of gabapentin
|
|
MX2021003653A
(es)
|
2018-10-11 |
2021-06-23 |
Sanifit Therapeutics S A |
Inositol fosfatos para el tratamiento de calcificacion ectopica.
|
|
CA3159067A1
(en)
*
|
2019-10-25 |
2021-04-29 |
Kyoto University |
Preventative or therapeutic agent for tauopathy
|
|
CA3170635A1
(en)
|
2020-03-04 |
2021-09-10 |
Ginger D. Constantine |
Methods and compositions for treating cannabis use disorder and mitigating cannabinoid withdrawal
|
|
EP4015494A1
(en)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Processes for the preparation of soluble salts of inositol phosphates
|
|
GB2625579A
(en)
|
2022-12-21 |
2024-06-26 |
Novumgen Ltd |
An orally disintegrating tablet containing gabapentin or pharmaceutically acceptable salts thereof and the process of preparing the same
|
|
WO2026034064A1
(ja)
*
|
2024-08-09 |
2026-02-12 |
株式会社カネカ |
ビシクロヘプテン系化合物、及びビシクロヘプテン系化合物の製造方法
|
|
WO2026085523A1
(en)
*
|
2024-10-18 |
2026-04-23 |
Schem Corp. |
A process for preparation of gabapentin
|